Preclinical toxicology of alofanib, an allosteric inhibitor of fibroblast growth factor receptor 2

Background. Inhibition of fibroblast growth factor receptor type 2 (FGFR2) appears to be appropriate in patients with tumors expressing or amplifying FGFR2. The toxicity of allosteric FGFR2 inhibitors has not been previously studied.

Purpose. Evaluation of the toxicity of the anticancer drug alofanib (RPT835), allosteric inhibitor of fibroblast growth factor receptor 2 type (FGFR2), in standard experimental in-vivo models in rodents and non-rodents.

Material and methods. The general toxic effect of the alofanib was studied in an acute and chronic experiment on outbred animals (rats and rabbits) of both sexes. An experimental study was conducted in accordance with the ethical principles of handling laboratory animals.

Results. The assumption that inhibition of FGFR2 provides a low level of toxicity has been proved. It was established that alofanib belongs to the 4 class of low-toxic chemical substances according to the classification of hazard levels of toxic effects of drugs and to the low-risk drugs by the value of the index of the therapeutic action, as well as to the 3 class (low-toxic drugs) according to the class of hazards for clinical application. Alofanib doesn»t cause allergenic and immunotoxic effects as well as doesn»t have pyrogenic properties. Increase of phosphates level (class-specific adverse effect of FGFR2 inhibitors) was statistically significant but less evident. During the study was noticed such an adverse effect as inhibition of spermatogenesis.

Conclusion. Alofanib belongs to the classes of low-hazard and low-toxic chemicals and can be studied in a clinical study.

1. Imyanitov EN, Demidova IA, Gordiev MG, Filipenko ML, et al. Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer. Mol Diagn Ther. 2016 Aug;20 (4):401-406.

2. Бесова Н. С., Бяхов М. Ю., Константинова М. М., Лядов В. К. с соавт. Практические рекомендации по лекарственному лечению рака желудка // Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 273-288

3. Тимофеев И.В., Варламов И.С., Петкау В.В., Сафина С.З. с соавт. Продолжительность жизни больных метастатическим почечно-клеточным раком в Российской Федерации: результаты многоцентрового регистрового исследования RENSUR3. Злокачественные опухоли. 2019;9 (2):45-52.

4. Demidova I, Grinevich V, Avdalian A, Imyanitov E, et al. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches. Lung Cancer. 2017 Jan;103:17 -23.

5. Tsimafeyeu I, Khasanova A, Stepanova E, Gordiev M, Khochenkov D, Naumova A, Varlamov I, Snegovoy A, Demidov L. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma. Clin Transl Oncol. 2017 Feb;19 (2):265-268.

6. Tsimafeyeu I, Daeyaert F, Joos JB, Van Aken K, et al. Molecular modeling, de novo design and synthesis of a novel, extracellular binding fibroblast growth factor receptor 2 inhibitor alofanib (RPT835). Medicinal Chemistry, 2016, 12, 1-15.

7. Хоченков Д. А., Степанова Е. В. Антиангиогенная активность Алофаниба — аллостерического ингибитора рецептора 2-го типа фактора роста фибробластов // Бюллетень экспериментальной биологии и медицины, 2015, 2015.-N 7.-С. 96-100.

8. Tsimafeyeu I, Ludes-Meyers J, Stepanova E, Daeyaert F, Kochenkov D, Joose JB, Solomko E, Van Akene K, Peretolchina N, Yin W, Ryabaya O, Byakhov M, Tjulandin S. Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumor models. Eur J Cancer. 2016 Jul;61:20 - 8.

9. Руководство по содержанию и использованию лабораторных животных, (FELASA), 2010

10. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. — М.: Гриф и К, 2012. — 944 с.

11. Государственная фармакопея Российской федерации, XIII издание, ч. 1, 2016).

12. Березовская И. В. Классификация химических веществ по параметрам острой токсичности при парентеральных способах введения, Химико-фармацевтический журнал, Т. 37, № 3, 2003.

13. Tsimafeyeu I, Bratslavsky G. Fibroblast growth factor receptor1 as a target for the therapy of renal cell carcinoma. Oncology. 2015;88 (6):321-31.

14. Tyulyandina A, Harrison D, Yin W, Stepanova E, et al. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies. Invest New Drugs. 2017 Apr;35 (2):127 - 133.